Symbol Lookup

Monday August 03, 2015 11:05 AM ET. Data delayed 15 minutes.
21.38
0.07 (0.35%)
Bid/Lots
21.33/2
Ask/Lots
21.42/1
Open/Prev Close
21.50/21.31
Day Range
21.14-22.35
52-Week Range
7.53-22.35
Vol/Avg Daily Vol
296.9K/1.2M

TD Waterhouse offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

CARA Headlines

Go
An Encouraging Turn in the Study - Report on Cara Therapeutics Inc.
9:20AM ET on Friday Jul 31, 2015 by PR Newswire
Companies Mentioned: CARA

ACI Association has initiated research coverage on Cara Therapeutics Inc. (NASDAQ: CARA). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the research available to new members.

ACI Association has initiated research coverage on Cara Therapeutics Inc. (NASDAQ: CARA). Select highlights from the internally released reports are being made available to the general public (included below), with access to the entirety of the...

Jul 29, 2015

Cara Therapeutics Announces Pricing of Its Public Offering of Common Stock
7:10PM ET on Wednesday Jul 29, 2015 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the pricing of its underwritten public offering of 3,763,440 shares of its common stock at a public offering price of $18.60 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Cara Therapeutics, are expected to be approximately $70 million. In addition, Cara Therapeutics granted the underwriters a 30-day option to purchase up to 564,516 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. All of the shares in the offering will be sold by Cara Therapeutics.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced the pric...

Jul 27, 2015

MT Newswires After-Hours News Movers
5:40PM ET on Monday Jul 27, 2015 by Midnight Trader
Companies Mentioned: GIG, HLIT, MPWR, MSTR, RCII, RCL, BIDU, ACI, AMKR, AVB, IPHS, TACO, CARA, AMDA, KN, CDNS, CKEC, COST
05:40 PM EDT, 07/27/2015 (MT Newswires) -- Some of the stocks moving on news-driven events in Monday's after-hours include: GIG, +7.2% MSTR, +6.9% KN, +5.9% CDNS, +3.1% ACI, +1.4% HLIT, +0.5% MPWR, +0.4% AVB, +0.2% AMDA, -37.4% AMKR, -15.6% CKEC, -1...
05:40 PM EDT, 07/27/2015 (MT Newswires) -- Some of the stocks moving on news-driven events in Monday's after-hours include: GIG, +7.2% MSTR, +6.9% KN, +5.9% CDNS, +3.1% ACI, +1.4% HLIT, +0.5% MPWR, +0.4% AVB, +0.2% AMDA, -37.4% AMKR, -15.6% CKEC,...
Cara Therapeutics Starts Public Stock Offering of Up to $65 Mln - Stock Drops in After-Hours
4:36PM ET on Monday Jul 27, 2015 by Midnight Trader
Companies Mentioned: CARA
04:36 PM EDT, 07/27/2015 (MT Newswires) -- Cara Therapeutics (CARA) said on Monday it started an underwritten public offering of $65 million of common stock. Shares in the Shelton, Connecticut-based biopharmaceutical company fell 6.7% in recent aft...
04:36 PM EDT, 07/27/2015 (MT Newswires) -- Cara Therapeutics (CARA) said on Monday it started an underwritten public offering of $65 million of common stock. Shares in the Shelton, Connecticut-based biopharmaceutical company fell 6.7% in recent ...
Cara Therapeutics Announces Proposed Offering of Common Stock
4:20PM ET on Monday Jul 27, 2015 by GlobeNewswire
Companies Mentioned: CARA

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it has commenced an underwritten public offering of shares of its common stock of up to $65 million. In addition, Cara Therapeutics expects to grant the underwriters a 30-day option to purchase an additional 15% of the number of shares of common stock sold on the same terms and conditions. All of the shares in the offering will be sold by Cara Therapeutics.

Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors, today announced that it ...

← Newer123Older →

Peers Headlines

Today

Bellicum Pharmaceuticals to Present at the 2015 Wedbush PacGrow Healthcare Conference
3 hours ago by Business Wire
Companies Mentioned: BLCM

Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced that management will present a corporate overvie...

Dermira Doses First Patients in DRM04 Phase 3 Program in Axillary Hyperhidrosis
3 hours ago by GlobeNewswire
Companies Mentioned: DERM

Two Identical Studies to Enroll a Combined Total of 660 Patients

Topline Phase 3 Data Expected in the Second Half of 2016

Represents Dermira's Second Product Candidate in Phase 3 Development

Dermira Updates 2015 Financial G...

Jul 28, 2015

XBiotech Provides Second Quarter 2015 Corporate and Clinical Update
6:30AM ET on Tuesday Jul 28, 2015 by GlobeNewswire
Companies Mentioned: XBIT

Recent Highlights:

-- Completed initial public offering April 17, 2015

-- Enrolled first patient in global Phase 3 study of Xilonix(TM) for treating metastatic colorectal cancer under revised protocol

Jul 16, 2015

Bellicum Appoints Stephen R. Davis to Board of Directors
4:05PM ET on Thursday Jul 16, 2015 by Business Wire
Companies Mentioned: ACAD, BLCM

Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Stephen R. Davis to its Boar...

Jul 15, 2015

XBiotech to Provide Second Quarter Business Update
9:18AM ET on Wednesday Jul 15, 2015 by GlobeNewswire
Companies Mentioned: XBIT

XBiotech Inc., (NASDAQ:XBIT), the world's leading developer of next-generation True Human(TM) therapeutic antibodies, will host its inaugural quarterly business update conference call and live webcast on July 28, 2015, at 8:30am Eastern Time. T...

Jul 7, 2015

XBiotech Posts Findings from Clinical Testing of True Human Antibody Therapy for Type 2 Diabetes
7:55AM ET on Tuesday Jul 07, 2015 by Midnight Trader
Companies Mentioned: XBIT
07:55 AM EDT, 07/07/2015 (MT Newswires) -- XBiotech (XBIT) Tuesday said the results of a clinical study it conducted on its True Human antibody therapy for treatment of Type 2 diabetes have now been published in the Journal of Diabetes and its Co...
XBiotech Announces Publication of Clinical Results Supporting Its True Human(TM) Antibody Therapy for Type 2 Diabetes Mellitus
7:35AM ET on Tuesday Jul 07, 2015 by GlobeNewswire
Companies Mentioned: XBIT

XBiotech (NASDAQ:XBIT), the world's leading developer of next-generation True Human(TM) therapeutic antibodies, announced publication of clinical results from an open label pilot study for its antibody therapy for treatment of Type 2 diabetes. ...

Jul 6, 2015

XBiotech Inc. Treats 1st Patient in Phase 1/2 Clinical Study of True Human Therapeutic Antibody to Treat Serious Infections Due to Staphylococcus aureus
7:37AM ET on Monday Jul 06, 2015 by Midnight Trader
Companies Mentioned: XBIT
07:37 AM EDT, 07/06/2015 (MT Newswires) -- XBiotech Inc. (XBIT) says it treated its first patient in its Phase 1/2 clinical study designed to evaluate dosing, safety and efficacy of a novel antibody therapy intended to treat all forms of Staphylo...
XBiotech Treats First Patient in Phase 1/2 Clinical Study of Novel True Human(TM) Therapeutic Antibody for Treating Serious Infections Due to Staphylococcus aureus
7:35AM ET on Monday Jul 06, 2015 by GlobeNewswire
Companies Mentioned: XBIT

XBiotech Inc. (NASDAQ:XBIT), world's leading developer of next-generation True Human(TM) therapeutic antibodies, announced today treatment of first patient in its Phase 1/2 clinical study. The study is designed to evaluate dosing, safety and ef...